开发一种机器学习模型,以帮助预测药物耐药的儿童的治疗成功
Achmad Rafli1,2, Wisnu Ananta Kusuma3,4, Setyo Handryastuti2
1Doctoral Program in Medical Sciences, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Frontiers in neurology
|December 19, 2025
概括
机器学习模型可以预测药物耐药的儿童的治疗成功. 整合临床数据,EEG和MRI有助于个性化抗药物选择,以更好地控制发作.
科学领域:
- 神经学 神经学
- 人工智能的人工智能
- 儿科医学 儿科医学
背景情况:
- 儿童耐药性 (DRE) 由于患者的变异性而带来了重大治疗挑战.
- 目前的抗药物 (AED) 选择往往难以在儿科DRE中实现一致的发作减少.
- 个性化治疗策略对于改善儿科的结果至关重要.
研究的目的:
- 开发和评估机器学习模型,用于预测患有DRE的儿科患者的治疗成功.
- 确定最佳的机器学习算法,用于预测治疗结果.
- 为管理儿科DRE的临床医生创建一个决策支持工具.
主要方法:
- 研究了215名患有DRE的儿科患者的雄心勃勃的队列.
- 数据包括临床信息,脑电图 (EEG) 和磁共振成像 (MRI).
- 机器学习算法 (SVM,DT,RF,GB) 被使用并对预测性能进行了比较.
主要成果:
- 机器学习模型整合了各种数据类型,以预测治疗成功.
- 对比分析确定了预测控制的最有效算法.
- 这项研究建立了一种新的方法,用于预测儿科DRE的治疗反应.
结论:
- 机器学习提供了一个有前途的方法来个性化为儿科DRE的AED选择.
- 开发的模型可以帮助神经科医生预测控制和指导治疗调整.
- 这项研究开创了在印度尼西亚用于DRE管理的机器学习集成数据的使用.
更多相关视频
09:49Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
Published on: June 29, 2022
3.1K
09:29Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
Published on: August 17, 2021
2.8K
相关概念视频
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
790
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
790
